Kura Oncology, Inc. KURA
8.04 USD -1.84 (-18.62%)
Nov 4, 2026, 2:22 PM EST
7.88 Day range 10.21
7.36 52-week range 13.90
- YTD
- -22.62%
- 1 year
- -19.28%
- Market cap
- 716.26M
- Revenue (ttm)
- 77.22M
- EPS (ttm)
- -3.40
- Shares out
- 88.96M
- Forward P/E
- -5.11
- YTD return
- -22.62%
- 1-year return
- -19.28%
- Volume
- 4.91M
- Avg volume
- 1.90M
- Open
- 10.21
- Previous close
- 9.88
- Day's range
- 7.88 – 10.21
- 52-week range
- 7.36 – 13.90
- Beta
- 0.43
- Analysts
- Strong Buy
- Price target
- 32.00 (+298.0%)
- Earnings date
- Nov 3, 2026
MAX -5.88 (-36.75%)
Key statistics
- Enterprise value
- 537.37M
- PEG ratio
- 0.00
- Price / sales
- 13.51
- Price / book
- 21.56
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 36.50%
- Free cash flow
- -165.88M
- Total cash
- 519.02M
- Total debt
- 24.45M
- Return on equity
- -167.71%
- Short % of float
- 15.48%
- 50-day average
- 11.17
- 200-day average
- 9.82
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 32.00 +298.0% upside
Now 8.04
- Target (low)
- 15.00
- Target (mean)
- 32.00
- Target (high)
- 76.00
Ratings (0m) 15 14 buy · 1 hold · 0 sell
- Strong buy2
- Buy12
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -0.80667.
Financials — quick view
KURA Revenue — quarterly 20.87M
KURA Net income — quarterly -68.33M
KURA EPS — quarterly -0.77
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.84 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.87733 | -0.77 | +0.11 | +12.23% |
| May 12, 2026 | Mar 31, 2026 | -0.88 | -0.83 | +0.05 | +5.68% |
| Mar 5, 2026 | Dec 31, 2025 | -0.72 | -0.92 | -0.20 | -27.78% |
| Nov 4, 2025 | Sep 30, 2025 | -0.57 | -0.85 | -0.28 | -49.12% |
| Aug 7, 2025 | Jun 30, 2025 | 0.15 | -0.75 | -0.90 | -600.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 24, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| Aug 13, 2026 | Wedbush | main | Outperform | Outperform |
| Jul 28, 2026 | Wedbush | reit | Outperform | Outperform |
| Jun 15, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| Apr 14, 2026 | Lake Street | init | — | Buy |
| Mar 24, 2026 | Mizuho | main | Outperform | Outperform |
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kuraoncology.com
News
Reported Earlier: Kura Oncology And Kyowa Kirin To Present Eight Ziftomenib Abstracts At ASH 2026, Highlighting Promising AML Combination Data And Expanded Clinical Potential 
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026 
Kura Oncology to Report Third Quarter Financial Results on November 10 
Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know 
Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor 
Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript 
Caspian Therapeutics, Kura Oncology Plan To Devise Development Strategy For Caspian's KO-7246 Oral Menin Inhibitor Designed For Diabetes And Other Chronic Metabolic Diseases 
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes 
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes 
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Your note
Sign in to keep a note on KURA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAIR TERESA BROPHY | Officer | Sale | Aug 18, 2026 | 195,444 |
| BURROWS FRANCIS J. PH.D. | Officer | Sale | Jan 26, 2026 | 32,424 |
| DOYLE THOMAS JAMES | Officer | Sale | Jan 26, 2026 | 145,667 |
| FORD KATHLEEN | Chief Operating Officer | Sale | May 18, 2026 | 153,560 |
| HASNAIN FAHEEM | Director | Conversion of Exercise of derivative security | Dec 8, 2025 | 23,983 |
| LEONI MOLLIE M.D. | Officer | Sale | Jun 17, 2026 | 182,345 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 11.81% | 10,509,233 | 123.27M | Jun 29, 2026 |
| Montanova Capital LLC | 9.64% | 8,575,422 | 100.59M | Jun 29, 2026 |
| BVF Inc. | 9.49% | 8,445,769 | 99.07M | Jun 29, 2026 |
| State Street Corporation | 5.99% | 5,329,208 | 62.51M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.40% | 3,916,164 | 45.94M | Jun 29, 2026 |
| Armistice Capital, LLC | 4.13% | 3,678,000 | 43.14M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.40% | 3,020,727 | 35.43M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.15% | 2,799,338 | 32.84M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.44% | 2,168,959 | 25.44M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.15% | 1,026,943 | 12.05M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.04% | 921,604 | 10.81M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.88% | 780,455 | 9.15M | Jul 30, 2026 |